BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37384207)

  • 21. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.
    Al-Katib AM; Mensah-Osman E; Aboukameel A; Mohammad R
    Semin Oncol; 2003 Apr; 30(2):313-7. PubMed ID: 12720160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
    Vitolo U; Ferreri AJ; Montoto S
    Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM).
    Chiappella A; Ciochetto C; Orsucci L; Vitolo U
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):149-51. PubMed ID: 21454219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term Survival in a Patient With Transformation of Waldenström's Macroglobulinemia into DLBCL.
    Solia E; Ntanasis-Stathopoulos I; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
    Cancer Diagn Progn; 2024; 4(1):77-80. PubMed ID: 38173665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel agents in Waldenstrom Macroglobulinemia.
    Sacco A; Leleu X; Rossi G; Ghobrial IM; Roccaro AM
    Open J Hematol; 2010 May; 1():. PubMed ID: 22844582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A safety profile of medications used to treat Waldenström's macroglobulinemia.
    García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
    Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How we treat Waldenström's macroglobulinemia.
    Dimopoulos MA; Merlini G; Leblond V; Anagnostopoulos A; Alexanian R
    Haematologica; 2005 Jan; 90(1):117-25. PubMed ID: 15642678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Waldenström's macroglobulinemia].
    Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
    Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of diffuse large B-cell lymphoma in a patient with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms.
    Shiseki M; Masuda A; Watanabe N; Fujii M; Kimura T; Yoshinaga K; Mori N; Teramura M; Motoji T
    Hematol Rep; 2011 Aug; 3(2):e10. PubMed ID: 22184531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
    Kapoor P; Paludo J; Abeykoon JP
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):671-687. PubMed ID: 37246086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
    D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
    J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waldenström's macroglobulinemia with necrotic extremities: A case with challenging diagnosis.
    Nekooghadam SM; Ghadirzadeh E; Lapevandani MM; Ghorbani P; Yazdi YG; Shafiei S; Rakhshan A; Paraandavaji E; Charkazi E
    Clin Case Rep; 2023 Sep; 11(9):e7809. PubMed ID: 37663818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Waldenstrom's macroglobulinemia associated with Hodgkin's lymphoma: a case report.
    Fu Y; Zhu H; Liu P
    J Biomed Res; 2013 Jun; 29(6):508-11. PubMed ID: 26273017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
    Sekiguchi N
    Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current options to manage Waldenström's macroglobulinemia.
    Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
    Kaedbey R; Forward N; Sehn LH; Shafey M; Doucette S; Chen CI
    Curr Oncol; 2022 Sep; 29(10):7122-7139. PubMed ID: 36290837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.